185 related articles for article (PubMed ID: 17034142)
1. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
Moyle PM; Olive C; Ho MF; Good MF; Toth I
J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
[TBL] [Abstract][Full Text] [Related]
2. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
Moyle PM; Olive C; Good MF; Toth I
J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
[TBL] [Abstract][Full Text] [Related]
3. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
[TBL] [Abstract][Full Text] [Related]
4. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
5. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
[TBL] [Abstract][Full Text] [Related]
9. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
[TBL] [Abstract][Full Text] [Related]
12. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation.
Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I
J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036
[TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
14. Towards the development of a broadly protective group a streptococcal vaccine based on the Lipid-Core Peptide system.
Olive C; Moyle PM; Toth I
Curr Med Chem; 2007; 14(28):2976-88. PubMed ID: 18220734
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope.
Simerska P; Lu H; Toth I
Bioorg Med Chem Lett; 2009 Feb; 19(3):821-4. PubMed ID: 19097790
[TBL] [Abstract][Full Text] [Related]
16. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
[TBL] [Abstract][Full Text] [Related]
17. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates.
Fujita Y; Abdel-Aal AB; Wimmer N; Batzloff MR; Good MF; Toth I
Bioorg Med Chem; 2008 Oct; 16(19):8907-13. PubMed ID: 18789866
[TBL] [Abstract][Full Text] [Related]
20. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
